Small S - Search Results

1

Overexpression of survivin initiates hematologic malignancies in vivo.

Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Small S, et al. Leukemia. 2010 Nov;24(11):1920-6. doi: 10.1038/leu.2010.198. Epub 2010 Sep 30. Leukemia. 2010. PMID: 20882051 Free PMC article.

2

Survivin is not required for the endomitotic cell cycle of megakaryocytes.

Wen Q, Leung C, Huang Z, Small S, Reddi AL, Licht JD, Crispino JD. Wen Q, et al. Among authors: small s. Blood. 2009 Jul 2;114(1):153-6. doi: 10.1182/blood-2008-11-190801. Epub 2009 Apr 1. Blood. 2009. PMID: 19339696 Free PMC article.

3

Vesicle trafficking plays a novel role in erythroblast enucleation.

Keerthivasan G, Small S, Liu H, Wickrema A, Crispino JD. Keerthivasan G, et al. Among authors: small s. Blood. 2010 Oct 28;116(17):3331-40. doi: 10.1182/blood-2010-03-277426. Epub 2010 Jul 19. Blood. 2010. PMID: 20644112 Free PMC article.

4

Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections.

Mina A, Small S, Platanias LC. Mina A, et al. Among authors: small s. Leuk Lymphoma. 2021 Jun;62(6):1284-1286. doi: 10.1080/10428194.2021.1897808. Epub 2021 Mar 17. Leuk Lymphoma. 2021. PMID: 33729089 No abstract available.

5

Interferon maintenance for prevention of relapse in favorable risk AML?

Small SH, Altman JK, Platanias LC. Small SH, et al. Leuk Lymphoma. 2021 Dec;62(12):2818-2819. doi: 10.1080/10428194.2021.1966790. Epub 2021 Sep 3. Leuk Lymphoma. 2021. PMID: 34477023 No abstract available.

6

Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.

Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, Small D. Baldwin BR, et al. Among authors: small s, small d. Leukemia. 2007 Apr;21(4):764-71. doi: 10.1038/sj.leu.2404532. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268528

7

Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies.

Small S, Numan Y, Platanias LC. Small S, et al. Biomedicines. 2021 Nov 6;9(11):1631. doi: 10.3390/biomedicines9111631. Biomedicines. 2021. PMID: 34829860 Free PMC article. Review.

8

Role of Biomarkers in the Management of Acute Myeloid Leukemia.

Small S, Oh TS, Platanias LC. Small S, et al. Int J Mol Sci. 2022 Nov 22;23(23):14543. doi: 10.3390/ijms232314543. Int J Mol Sci. 2022. PMID: 36498870 Free PMC article. Review.

9

B Cell Lymphomas of the GI Tract.

Small S, Barnea Slonim L, Williams C, Karmali R. Small S, et al. Curr Gastroenterol Rep. 2021 May 8;23(7):9. doi: 10.1007/s11894-021-00811-8. Curr Gastroenterol Rep. 2021. PMID: 33963950 Review.

10

Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.

Small S, Ma S. Small S, et al. Curr Hematol Malig Rep. 2021 Aug;16(4):325-335. doi: 10.1007/s11899-021-00637-1. Epub 2021 May 22. Curr Hematol Malig Rep. 2021. PMID: 34021874 Review.

PURPOSE OF REVIEW: The treatment options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have expanded significantly in the last few years, including the use of new classes of oral small molecular inhibitors targeting the B cell receptor signal …

PURPOSE OF REVIEW: The treatment options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have expanded signific …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

731 results

Search Page